GRP and neoplasm: In conclusion, our study identified pre-chemotherapy tumor size and post-cycle 2 FIB levels as independent predictors of treatment efficacy, and pre-chemotherapy WBC count, pre-chemotherapy D-dimer, and post-cycle 2 gastrin-releasing peptide precursor as independent risk factors for OS in ES-SCLC patients receiving first-line systemic therapy.